

9 March 2023



The Nifty ended 0.93% down at 17589.60. It opened on a flat note and got sold off towards ending with a huge bearish candle. failing to breakout resistance placed around 17800 suggesting pullback may again find sellers on rise. Hence, staying cautious on rise is advised. Immediate resistance is placed around 17650 levels. The Nifty intraday range likely to be 17450-17650 with a negative bias.

On the Nifty hourly chart, it reacted down exactly from the critical MA band placed around 17800 levels and closed below 17650 levels. Staying cautious on rise is advised. Further weakness is likely.

Nifty patterns on multiple periods suggesting; closing below 17650 suggesting further weakness propelled by correction in Index majors. Hence, sell on rise is advised.

Nifty Crucial Supports & Resistances-

Supports- 17550, 17450 Resistances- 17650, 17800

Open Positional Calls-


T+15 SELL-

| Fut Segment | HINDALCO @ 420-425, TGT- 385, Closing SL- above 445

T+30 INST POSITIONAL SELL-

| Fut Segment | CAN BANK @ 310-315, TGT- 275, Closing SL- above 335

Nifty Intraday Chart



Market in Retrospect

India's benchmark stock indices fell the most in a single day in more than two weeks on Thursday, ending their three-day winning streak on fears of faster rate hikes.

Nifty index ended 0.93% lower, ended at 17,590. The broader markets represented by the Nifty 500 Index ended 0.79% higher, ending at 14,804. Among the sectorial indices, Nifty Metal was the only gainer gaining by 0.06%. Nifty Auto was the top loser losing by 1.83%.

Tata Steel was the top gainer, gaining by 1.60%, followed by L&T and Apollo Hospitals which gaining by 1.03% & 0.96%. Adani Enterprises was the top loser, losing by 4.24%, followed by M&M and SBI Life Insurance losing by 3.24% & 2.88%.

Market Turnover (In Crore) 09-03-2023

Name	Last	Previous
NSE Cash	47885.07	51066.51
NSE F&O	36842551.67	18655937.04
BSE Cash	3,209.24	3,264.47
BSE F&O	*NA	25.66

FII Derivatives Flow (In Crore) 08-03-2023*

Instrument	Purchase	Sale	Net
Index Future	5207.90	5784.48	576.58
Index Option	1332485.34	1327936.91	4548.43
Stock Future	8452.31	8334.20	118.11
Stock Option	9310.45	9220.28	90.17

Institutional Flow (In Crore) 09-03-2023

Institution	Purchase	Sale	Net
FII	7570.52	8132.30	561.78
DII	4806.0	4564.29	42.41

*Data not updated till 6.54PM

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Tata Steel	1.60	2.56	51967449	79886920
Larsen & Toubro	1.03	3.68	1873933	1944827
Apollo Hospitals	0.96	0.10	684685	251704
Bharti Airtel	0.89	3.09	5240056	4511839
Axis Bank	0.80	0.31	14746065	10758150

NIFTY Top Losers


Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Adani Ports & SE	2.08	15.80	17041388	28048520
Reliance Industries	2.40	0.65	7492509	5674885
SBI Life Insurance	2.88	1.92	1239659	793907
M&M	3.24	1.89	3596577	1867437
Adani Enterprises	4.24	24.86	12627794	22144570

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>



Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	59806.28	541.81	0.90	0.67	1.44	3.82	7.83
Nifty	17589.60	164.80	0.93	0.79	1.49	4.90	5.99
BSE M Cap	24789.01	136.17	0.55	1.24	0.37	5.01	7.96
BSE S Cap	28117.40	56.06	0.20	1.44	0.04	4.88	5.77
Nifty MC 100	30948.65	170.60	0.55	1.19	0.26	4.40	10.38
BSE Auto	29404.39	512.45	1.71	0.29	3.23	0.73	28.71
BSE Capgoods	34914.57	101.14	0.29	1.97	1.04	0.54	29.70
BSE FMCG	16368.11	152.78	0.92	0.89	0.58	2.27	28.77
BSE Metal	19680.01	120.25	0.61	1.02	1.93	4.32	9.38
BSE Oil&Gas	17648.48	123.53	0.70	3.37	0.47	13.25	1.58
BSE Healthcare	21682.47	13.41	0.06	0.00	3.12	7.26	7.83
BSE Power	3553.25	16.39	0.46	6.76	1.50	21.79	9.24
BSE Realty	3220.91	35.12	1.08	1.09	3.17	9.59	5.28
BSE ConsDur	37500.13	444.70	1.17	0.63	2.95	8.09	9.48
BSE Bank	46684.50	325.00	0.69	1.20	0.67	6.07	18.22
BSE IT	29495.28	286.49	0.96	1.04	4.36	0.50	15.75

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	4.00	0.01	0.15	1.44	9.28	11.71	104.66
UK	3.81	0.04	1.06	1.96	15.62	19.62	149.35
Brazil	6.64	0.01	0.11	0.47	7.06	16.05	29.16
Japan	0.51	0.00	0.20	0.20	1.40	97.66	202.99
Australia	3.71	0.04	0.96	3.96	1.04	12.50	60.06
India	7.43	0.01	0.11	0.39	1.12	1.75	8.44
Switzerland	1.45	0.00	0.21	6.80	8.35	25.78	397.95
Germany	2.69	0.04	1.51	2.36	16.63	38.96	1143.52

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	81.98	0.07	0.09	0.74	0.66	0.36	6.61
USD Index	105.40	0.26	0.25	0.35	2.11	0.56	7.58
YUAN	6.96	0.01	0.08	0.69	2.56	0.09	9.29
GBP	1.19	0.00	0.30	0.55	1.99	3.09	9.87
EUR	1.06	0.00	0.14	0.35	1.68	0.19	4.66
YEN	136.36	1.00	0.73	0.30	3.50	0.15	15.06

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1327.00	29.00	2.23	15.90	124.16	4.26	48.12
Baltic Dirty	1495.00	8.00	0.54	1.56	24.07	29.15	10.82
SG Dubai HY	25.48	2.40	10.40	18.81	23.37	24.22	638.25

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	32798.40	58.06	0.18	0.42	2.68	2.03	1.47
Nasdaq	11576.00	45.67	0.40	1.73	1.81	5.19	12.67
S&P 500	3992.01	5.64	0.14	1.03	2.19	1.46	6.68
FTSE100	7880.07	48.97	0.62	0.79	0.38	5.41	9.60
CAC40	7295.46	29.10	0.40	0.16	1.49	9.26	14.21
DAX	15559.74	74.97	0.48	1.50	0.22	8.25	12.34
Mexico IPC	53388.66	319.93	0.60	0.16	1.11	5.79	0.97
Brazil Bovespa	106540.3	2312.39	2.22	2.07	1.36	0.91	6.46
Russian RTS	950.60	0.72	0.08	0.54	3.17	13.31	1.46
Japan Nikkei	28623.15	178.96	0.63	4.09	3.44	2.59	11.42
Hang Seng	19925.74	125.51	0.63	2.47	5.97	0.12	4.62
Taiwan Index	15770.66	47.54	0.30	1.10	1.18	7.24	9.54
Shanghai Comp	3276.09	7.15	0.22	1.04	0.47	2.16	0.61
KOSPI	2419.09	12.82	0.53	0.36	2.05	1.26	9.75
Malaysia KLCI	1449.53	5.13	0.35	0.41	1.70	1.87	8.29
Jakarta Comp	6799.80	23.43	0.35	0.84	1.17	1.26	1.79
Philippine SE	6609.27	102.22	1.52	0.20	3.89	0.44	7.24
Thai Exch	1614.22	1.62	0.10	0.36	3.02	0.55	2.00

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	76.85	0.19	0.25	1.68	1.55	8.21	29.30
BRENT Crude	82.90	0.26	0.31	2.16	1.36	7.69	4.48
Natural Gas	2.63	0.08	3.25	4.74	5.70	46.51	26.12

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1817.94	4.33	0.24	0.97	2.34	1.16	8.72
Silver(\$/Ounce)	20.09	0.06	0.32	3.86	8.59	14.41	22.06
Aluminium	2305.69	4.94	0.21	3.33	5.59	6.66	33.56
Copper	8886.00	148.50	1.70	2.18	0.25	4.24	12.55
Zinc	3004.00	23.25	0.78	4.41	5.15	8.11	26.96
Lead	2086.50	4.50	0.22	2.52	2.27	5.11	15.22

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	176.80	0.55	0.31	2.96	1.78	11.23	19.45
Cotton	82.93	0.31	0.38	0.93	3.50	2.51	12.97
Sugar	20.82	0.06	0.29	2.51	4.05	12.78	12.78
Wheat	687.25	0.25	0.04	3.58	10.51	7.72	20.41
Soybean	1526.25	8.50	0.56	1.13	0.96	2.19	9.27

Alembic Pharma gets USFDA nod to market generic antidepressant drug

Alembic Pharmaceuticals has received an approval from the US health regulator to market a generic antidepressant medication in the American market. The company has received an approval from the US Food & Drug Administration to market Brexpiprazole tablets in strengths of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg. The company's product is therapeutically equivalent to Otsuka Pharmaceutical Co's reference listed drug product Rexulti tablets. Brexpiprazole tablets are indicated as an adjunctive therapy to antidepressants for the treatment of major depressive disorder and for the treatment of schizophrenia. According to IQVIA data, Brexpiprazole tablets in strengths of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg have an estimated market size of USD 1.6 billion for 12 months ended December 2022. The US market is the world's largest for pharmaceutical products. In 2021-22 fiscal, India's total pharma exports to global markets, including the US, stood at around Rs 1,75,040 crore.

Godrej Agrovet inks pact with AP govt to set up edible oils refining plant at Rs 100 crore

Godrej Agrovet Ltd has proposed to invest Rs 100 crore to set up a refining plant for edible oils in Andhra Pradesh. In a statement, the company said it has signed a Memorandum of Understanding (MoU) with the state government on the sidelines of Andhra Pradesh Global Investors Summit (APGIS) 2023. As a part of the MoU, Godrej Agrovet's oil palm business will be making an estimated investment of Rs 100 crore to set up a manufacturing facility for edible oil refinery and solvent extraction plant. The company already has 45,000 hectare area of oil palm plantation area in Andhra Pradesh (AP). The proposed new plant will have a projected refining capacity of 400 tonnes per day and will be set up in Seethanagaram, Eluru District in AP. This is company's first downstream project for value-added products in oil and fats.

Camera-fitted jacket mandatory for customs officials handling sea cargoes

Customs officials clearing cargo at sea ports will now sport jackets fitted with Body Worn Camera with video and audio recording facility. The Central Board of Indirect Tax and Customs (CBIC) has made it mandatory for all boarding officers engaged in sea Customs, starting from April 15. This will improve transparency and ease of doing business through leveraging technology, the Central Board of Indirect Tax and Customs said in a circular sent to all principals commissioners and chief commissioners of Customs.

Reliance Brings Back The Iconic Campa Cola

Reliance Consumer Products Ltd. has relaunched the aerated drinks brand Campa, spurring a battle of colas with the long-standing market leaders Coca-Cola Co. and PepsiCo Inc. The launch of this 50-year-old iconic brand is in line with the company's strategy to promote local brands that not only have a rich heritage, but also boast a deep-rooted connection with consumers due to their taste and flavours, according to Reliance Consumer. It was the entry of Coca-Cola, coupled with its intense battle for market share with arch-rival PepsiCo in early 1990s, that led to the decline of Campa and its eventual downfall. The Campa portfolio will initially include Campa Cola, Campa Lemon and Campa Orange in the sparkling beverage category, the , the FMCG arm of Reliance Retail Ventures Ltd. Reliance had bought Campa from its New Delhi-based parents Pure Drinks Group at a meagre Rs 22 crore a few months ago. Now, the relaunch has raised hopes of the revival for the iconic brand. The Campa range is being rolled out from Andhra Pradesh and Telangana. It is currently available only on JioMart and other Reliance Group retail outlets.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
No events	

Domestic Events

- India Foreign Exchange Reserve for March 03, 2023.
- India Industrial Production for January 2023.

Global Events

- BOJ Interest Rate Decision.
- The U.S. Unemployment Rate for February 2023.

Analyst Certification:

We /I, Jaydeb Dey Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
